These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28363768)

  • 1. Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients.
    Wojciechowska C; Romuk E; Nowalany-Kozielska E; Jacheć W
    Hellenic J Cardiol; 2017; 58(5):350-359. PubMed ID: 28363768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure.
    Wang CH; Yang NI; Liu MH; Hsu KH; Kuo LT
    Cardiol J; 2016; 23(5):563-572. PubMed ID: 27515479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients.
    Hu DJ; Xu J; Du W; Zhang JX; Zhong M; Zhou YN
    Int J Cardiovasc Imaging; 2016 Dec; 32(12):1725-1733. PubMed ID: 27566192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent and incremental prognostic value of novel cardiac biomarkers in chronic hemodialysis patients.
    Obokata M; Sunaga H; Ishida H; Ito K; Ogawa T; Ando Y; Kurabayashi M; Negishi K
    Am Heart J; 2016 Sep; 179():29-41. PubMed ID: 27595677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction.
    Tymińska A; Kapłon-Cieślicka A; Ozierański K; Budnik M; Wancerz A; Sypień P; Peller M; Balsam P; Opolski G; Filipiak KJ
    Dis Markers; 2019; 2019():9529053. PubMed ID: 31687050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-3 and ST2 as predictors of therapeutic success in high-risk patients undergoing percutaneous mitral valve repair (MitraClip).
    Dörr O; Walther C; Liebetrau C; Keller T; Sommer T; Boeder N; Bayer M; Bauer P; Möllmann H; Gaede L; Troidl C; Voss S; Bauer T; Hamm CW; Nef H
    Clin Cardiol; 2018 Sep; 41(9):1164-1169. PubMed ID: 29896861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of diabetes on the predictive value of heart failure biomarkers.
    Alonso N; Lupón J; Barallat J; de Antonio M; Domingo M; Zamora E; Moliner P; Galán A; Santesmases J; Pastor C; Mauricio D; Bayes-Genis A
    Cardiovasc Diabetol; 2016 Nov; 15(1):151. PubMed ID: 27809845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of galectin-3 with changes in left ventricular function in recent-onset dilated cardiomyopathy.
    Rieth AJ; Jung C; Gall H; Rolf A; Mitrovic V; Hamm CW; Sperzel J; Liebetrau C
    Biomarkers; 2019 Nov; 24(7):652-658. PubMed ID: 31305163
    [No Abstract]   [Full Text] [Related]  

  • 11. N-terminal pro brain natriuretic peptide to predict prognosis in dilated cardiomyopathy with sinus rhythm.
    Tigen K; Karaahmet T; Kahveci G; Tanalp AC; Bitigen A; Fotbolcu H; Bayrak F; Mutlu B; Basaran Y
    Heart Lung Circ; 2007 Aug; 16(4):290-4. PubMed ID: 17403613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2.
    Stojkovic S; Kaider A; Koller L; Brekalo M; Wojta J; Diedrich A; Demyanets S; Pezawas T
    J Cell Mol Med; 2018 Apr; 22(4):2422-2429. PubMed ID: 29397580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
    Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
    Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Soluble ST2 Serum Levels With Outcomes in Pediatric Dilated Cardiomyopathy.
    You H; Jiang W; Jiao M; Wang X; Jia L; You S; Li Y; Wen H; Jiang H; Yuan H; Huang J; Qiao B; Yang Y; Jin M; Wang Y; Du J
    Can J Cardiol; 2019 Jun; 35(6):727-735. PubMed ID: 31151708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin-3, and NT-ProBNP Before Cardiac Surgery.
    Polineni S; Parker DM; Alam SS; Thiessen-Philbrook H; McArthur E; DiScipio AW; Malenka DJ; Parikh CR; Garg AX; Brown JR
    J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 29982227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiles of cardiovascular biomarkers according to severity stages of Chagas cardiomyopathy.
    Echeverría LE; Rojas LZ; Calvo LS; Roa ZM; Rueda-Ochoa OL; Morillo CA; Muka T; Franco OH
    Int J Cardiol; 2017 Jan; 227():577-582. PubMed ID: 27839809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.
    Demissei BG; Cotter G; Prescott MF; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Severin TM; Wang Y; Qian M; Teerlink JR; Metra M; Davison BA; Voors AA
    Eur J Heart Fail; 2017 Aug; 19(8):1001-1010. PubMed ID: 28133908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic utility of anemia and pro-B-type natriuretic peptide in patients with nonischemic dilated cardiomyopathy and normal renal function.
    Tigen K; Karaahmet T; Cevik C; Gurel E; Mutlu B; Basaran Y
    Am J Med Sci; 2009 Feb; 337(2):109-15. PubMed ID: 19214026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ST2 as a novel prognostic marker in end-stage renal disease patients on hemodiafiltration.
    Homsak E; Ekart R
    Clin Chim Acta; 2018 Feb; 477():105-112. PubMed ID: 29221927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble ST2 Receptor: Biomarker of Left Ventricular Impairment and Functional Status in Patients with Inflammatory Cardiomyopathy.
    Obradovic DM; Büttner P; Rommel KP; Blazek S; Loncar G; von Haehling S; von Roeder M; Lücke C; Gutberlet M; Thiele H; Lurz P; Besler C
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.